BioCryst Pharmaceuticals Provides 2026 Operating Expense and ORLADEYO Revenue Guidance
BioCryst Pharmaceuticals (BCRX) has released its financial outlook for 2026, projecting operating expenses to fall between $415 million and $425 million. The company also provided revenue guidance for its key product, ORLADEYO, estimating sales in the range of $625 million to $645 million. CEO Charles Gayer noted that the third quarter represented a period of significant execution during a phase of strategic evolution for the firm. The guidance reflects management's expectations for continued commercial momentum and controlled spending as the company navigates its current growth trajectory.
Tickers: $BCRX
Topics: earnings report management outlook quarterly results